Abstract
We report the activity of the new glycylcycline antimicrobial agent GAR-936 against 37 clinical isolates of vancomycin-resistant enterococci (including organisms carrying the vanA, vanB, vanC-1, and vanC-2/3 genes), 26 clinical isolates of methicillin-resistant S. aureus and 30 clinical isolates of high-level penicillin-resistant S. pneumoniae. All isolates of vancomycin-resistant enterococci, methicillin-resistant S. aureus, and penicillin-resistant S. pneumoniae were inhibited by < or = 1, < or = 2, or < or = 0.25 microg/ml of GAR-936, respectively. Time kill experiments using vancomycin-resistant enterococci did not demonstrate synergy or antagonism between 2 microg/ml of GAR-936 and 0.25 microg/ml of quinupristin/dalfopristin.
MeSH terms
-
Anti-Bacterial Agents / pharmacology*
-
Drug Resistance, Microbial
-
Drug Synergism
-
Drug Therapy, Combination / pharmacology
-
Enterococcus / classification
-
Enterococcus / drug effects*
-
Enterococcus / genetics
-
Enterococcus / isolation & purification
-
Gram-Positive Bacterial Infections / microbiology
-
Humans
-
Methicillin Resistance
-
Microbial Sensitivity Tests / methods
-
Minocycline / analogs & derivatives*
-
Minocycline / antagonists & inhibitors
-
Minocycline / pharmacology*
-
Penicillin Resistance
-
Staphylococcus aureus / drug effects*
-
Streptococcus pneumoniae / drug effects*
-
Tigecycline
-
Vancomycin Resistance / genetics
-
Virginiamycin / pharmacology
Substances
-
Anti-Bacterial Agents
-
Virginiamycin
-
quinupristin-dalfopristin
-
Tigecycline
-
Minocycline